News
Dr. Patrick Dennis Contributes to Herpes Zoster Research Published in CID
NEW ORLEANS, LA – Exciting progress continues to emerge in the ongoing effort to advance Herpes Zoster vaccine research, particularly in co-administration of RSVPreF3 and RZV and how it could improve vaccine coverage and reduce the number of vaccination visits for adults older than 50 years of age. Among the...
DelRicht Enrolls 126% of Expected Enrollment in a Phase 3 Pneumococcal Vaccine Trial
Selected as a participating site network for a Phase 3 Pneumococcal Vaccine trial, DelRicht Research was entrusted with enrolling healthy, pneumococcal-naïve adults across two specialized sites. From challenges including strict “pneumococcal-naïve” verification requirements for older populations and the technical barriers of 24-hour eDiary windows, DelRicht Research delivered through refined intake...
Proven Success in Psoriasis Trials: The DelRicht Difference
As the psoriasis landscape shifts toward targeted biologics and innovative topicals, DelRicht Research offers sponsors a premier partnership built on operational excellence. With 14 psoriasis trials completed, 130+ participants enrolled, and 8 experienced sites nationwide, our embedded network delivers high-quality data and rapid enrollment for even the most complex dermatology...
Dr. Robert Springer Contributes to COVID-19 Vaccine Research Presented at ESCMID Global 2026
ATLANTA, GA – Exciting progress continues to emerge in the ongoing effort to advance COVID-19 vaccine research, particularly as new variants reshape the global health landscape. A recent poster presentation, “Effectiveness and Safety of Variant-Updated COVID-19 Vaccines,” highlights the importance of continuously evolving vaccine strategies to maintain protection and improve...
Top 3 Enroller Studywide: Achieving 267% of the Goal in Phase 2 Obesity & T2DM Trial
DelRicht Research is proud to highlight the exceptional performance of Dr. Patrick Dennis and his team at Touro Medical Center in New Orleans, LA, whose site achieved top-tier enrollment results in a Phase 2 clinical trial focused on obesity and Type 2 diabetes (T2DM). Their ability to rapidly activate, enroll,...
What Happens When a Trial is Cancelled or Delayed: The Impact on Sites & Site Networks
Clinical research has always evolved through change. New science, shifting priorities, and even the difficult decisions to pause or cancel a study are part of the process that propels medicine forward. Recent insights from GlobalData show that roughly 4.7 percent of registered clinical trials are terminated, most often for reasons...
Dr. Patrick Dennis Featured as an Author on Recent Phase 2 Hypertension Manuscript
Uncontrolled hypertension remains a significant public health challenge, affecting millions of adults worldwide and increasing the risk of heart disease, stroke, and kidney failure. A recent publication, “Efficacy of Tonlamarsen in Patients with Uncontrolled Hypertension: The KARDINAL Phase 2 Randomized Clinical Trial,” provides important insight into a novel approach to...
Driving Success in Migraine Research: DelRicht Delivers Expertise and Enrollment Excellence
As migraine research continues to evolve, driven by increasing patient demand and a growing therapeutic pipeline, DelRicht Research stands out as a trusted partner for sponsors and CROs seeking both speed and precision. With more than 19 migraine trials completed over the past eight years, 740+ participants enrolled, and 17...
DelRicht Completes Enrollment as the Single Site Network in Recent COVID Study
DelRicht Research is proud to highlight the performance of its multi-site network in a U.S.-based Phase 3b/4 COVID-19 booster vaccine trial, where speed, coordination, and adaptability were critical to success. Exclusively selected as the site network for this study, DelRicht was tasked with enrolling both adolescent and adult populations across...
Dr. Robert Springer Featured as an Author on Recent COVID-19 Manuscript
The fight against COVID-19 continues to evolve as new variants emerge and public health priorities adapt. A recent publication, “Immunogenicity and safety of LP.8.1 variant-containing mRNA COVID-19 vaccines,” offers encouraging insight into how Moderna’s next-generation vaccines perform against the LP.8.1 subvariant and other circulating strains. DelRicht Research investigator Dr. Robert...
